EverSource Wealth Advisors’s Entrada Therapeutics TRDA Stock Holding History

EverSource Wealth Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.72K	Buy	642 +222	+53%	+$2.13K	﹤0.01%	3312
2026 Q1	$5.3K	Buy	420 +44	+12%	+$504	﹤0.01%	3241
2025 Q4	$3.87K	Sell	376 -13	-3%	-$110	﹤0.01%	3221
2025 Q3	$2.26K	Buy	389 +382	+5,457%	+$2.23K	﹤0.01%	3478
2025 Q2	$47	Buy	+7	New	+$56	﹤0.01%	4197
2025 Q1	–	Sell	-14	Closed	-$242	–	4174
2024 Q4	$242	Buy	+14	New	+$254	﹤0.01%	3394

Other funds holding TRDA

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

EverSource Wealth Advisors's TRDA Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Entrada Therapeutics (TRDA) stake by 53% in Q2 2026, buying an estimated $2.13K and bringing the position to 642 shares worth $4.72K. The position accounts for ﹤0.01% of the portfolio, ranked #3312.

EverSource Wealth Advisors first reported a position in TRDA in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.3K in Q1 2026. 23 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

EverSource Wealth Advisors held 642 shares of Entrada Therapeutics worth $4.72K as of Q2 2026.
EverSource Wealth Advisors bought 222 Entrada Therapeutics shares in Q2 2026, an estimated $2.13K.
Entrada Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3312 holding.
EverSource Wealth Advisors first reported a position in Entrada Therapeutics in Q4 2024 and has held it in 6 quarters since.
EverSource Wealth Advisors's Entrada Therapeutics position peaked at $5.3K in Q1 2026.
23 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.